Avalon Pharmaceuticals to Release First Quarter 2008 Results

  
    
  
  
    
      Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that it is 
      scheduled to release financial results for the first quarter of 2008 on 
      Wednesday, May 7, 2008 after the close of the U.S. financial markets. 
      The Company will also host a conference call on Thursday, May 8, 2008 at 
      8:30 am Eastern Time to provide a company update and discuss the 
      financial results for the quarter. Interested investors, analysts, 
      members of the media and the general public can listen to the call live 
      over the Internet or by dialing the numbers listed below.
    
    
      
        
          
            Conference Call details:
          
        
      
      
        
          Dial-In:
        
        
           
        
        
          [phone] (U.S.)
        
      
      
        
        
        
        
        
          [phone] (International)
        
      
      
        
          
             
          
        
        
        
        
          
            Passcode: 4845885
          
        
      
      
        
        
        
        
        
           
        
      
      
        
          Webcast:
        
        
        
        
          
            To access the call by live webcast, please visit the Investor 
            Relations section of our website at http://www.Avalonrx.com. 
            An archived version of the webcast will be available for 30 days.
          
        
      
    
    
      About Avalon Pharmaceuticals
    
    
      Avalon is a biopharmaceutical company focused on the discovery, 
      development and commercialization of first-in-class cancer therapeutics. 
      Avalon’s lead product candidate, AVN944, an 
      IMPDH inhibitor, is in Phase II clinical development. Avalon also has 
      preclinical programs to develop inhibitors of the Beta-catenin and 
      Aurora/Centrosome pathways, discovery programs for inhibitors of the 
      Survivin and Myc pathways and partnerships with Merck, 
      AstraZeneca/MedImmune, ChemDiv, Medarex, and Novartis. AvalonRx® 
      is the company’s proprietary platform which is 
      based on large-scale biomarker identification and monitoring, used to 
      discover and develop therapeutics for pathways that have historically 
      been characterized as "undruggable." Avalon is headquartered in 
      Germantown, MD.